这也在异种移植小鼠模型中得到了重现,即与 WT CLL CAR-T 细胞相比,CTLA4 缺陷小鼠的外周血 CAR-T 细胞中检测到细胞表面 CD28 的表达增加。基于这些数据,他们提出,CTLA4 在 CAR-T 细胞中的缺失导致了 CD28 信号的增强,从而维持了 CAR-T 细胞的共刺激和减少了 CAR-T 细胞功能障碍,这共同导致了 CAR-T 细胞...
A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell LymphomasWells, Drew A.Summerlin, JennaHalford, ZacheryJournal of Hematology Oncology Pharmacy
Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice doi:10.1002/jha2.338EJHaemSengsayadeth, SalykaSavani, Bipin N.Oluwole, OlalekanDholaria, Bhagirathbhai
很多研究证实,CD19 CAR-T治疗后,会出现肿瘤细胞CD19表达丢失;即使未丢失的患者,再次回输CD19 CAR-T的效果也很差。所以CD22 CAR-T治疗的最初目标是为了挽救这类CD19 CAR-T治疗失败的患者。 我们的研究结果显示,CD22 CAR-T治疗...
Globally, 300 clinical trials of CAR T-cell therapies have been approved by drug regulatory agencies spanning Europe, the US, Israel, China, and Australia.
CAR-T therapies are being explored worldwide. It was extremely pleased to see in Drs. Pan, Tong and et al.’s recently published paper in Leukemia describing their success in treating CD19 CAR-T refractory B-ALL patients with the novel CD22 CAR-T therapy. This pioneer study open the pos...
CARsgen is a biopharmaceutical company with operations inChinaand the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform, encompassing target discovery...
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. However, CAR immunotherapy in solid tumors lags significantly behind. Some of the major hurdles ...
These living drugs have taken the research community by storm, and the US Food and Drug Administration has approved several CAR-T cell therapies for blood cancers such aslymphomasand multiplemyeloma. But scientists are still struggling to work out whether these cells can be used to kill ‘solid...
19. Leick MB, et al. Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Mol Ther 2021; 29(2):433-441. 20.Leila A, et al. Preparing for CAR-T cell therapy: patient selection, bridging ther...